ATOMIC Trial ASCO 2025: Key Results Revealed
On June 1, 2025, the ASCO Annual Meeting in Chicago presented the ATOMIC trial ASCO 2025 results. This phase III study focuses on stage III dMMR colon cancer treatment. Researchers tested atezolizumab with mFOLFOX6 against mFOLFOX6 alone. The trial showed a clear improvement in disease-free survival for patients. This post explains the findings for oncology professionals.
Details of the ATOMIC Trial
The ATOMIC trial included 712 patients with dMMR stage III colon cancer. From 2017 to 2023, researchers divided them into two groups. One group of 355 patients received atezolizumab and mFOLFOX6. The other group of 357 patients got only mFOLFOX6. The median age was 64 years, and 55.1% were women. Also, 83.8% had proximal tumors. About 46.1% were low risk, while 53.9% were high risk.
Disease-Free Survival Data from ATOMIC Trial ASCO 2025
The results showed a difference in outcomes. Patients on atezolizumab with mFOLFOX6 had a three-year DFS of 86.4%. In contrast, the mFOLFOX6-only group had a DFS of 76.6%. The hazard ratio was 0.50, with a 95% CI of 0.35 to 0.72. Additionally, the p-value was below 0.0001. This exceeded the efficacy boundary of 0.009, confirming the benefit of the combined treatment.
Safety and Subgroup Analysis
Safety data highlighted some differences. The atezolizumab group had grade 3 or higher adverse events in 71.7% of cases. Meanwhile, the mFOLFOX6 group saw these events in 62.1% of patients. Importantly, the treatment was effective across all subgroups. This included both low-risk and high-risk patients, showing consistent results.
Implications for dMMR Colon Cancer Care
The ATOMIC trial ASCO 2025 findings may influence future treatment approaches. Adding atezolizumab to mFOLFOX6 improves DFS for dMMR stage III colon cancer. As a result, this combination could become a preferred option for adjuvant therapy. Oncologists may consider this approach to help patients stay cancer-free longer.
More ASCO 2025 Insights
Learn more about the ATOMIC trial ASCO 2025 results by viewing Erman Akkus’ infographic on X . For additional oncology research, explore our ASCO 2025 research page. Also, visit our colon cancer treatment updates for related information. Stay informed with the latest in cancer care.
Related Links:
https://dailynews.ascopubs.org/do/asco25-first-look-dr-julie-gralow-atomic?cid=DM21105&bid=498898895